prikaz prve stranice dokumenta Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography
  Preuzmi
PDF 645.56 KB
Znanstveni rad - Izvorni znanstveni rad
Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography
Digestive Diseases and Sciences, 67 (2021), 7; 3327-3332. https://doi.org/10.1007/s10620-021-07277-8
Podrug, Kristian; Trkulja, Vladimir; Zelenika, Marko; Bokun, Tomislav; Madir, Anita; Kanizaj, Tajana Filipec; O’Beirne, James; Grgurevic, Ivica

Citirajte ovaj rad

Podrug, K., Trkulja, V., Zelenika, M., Bokun, T., Madir, A., Kanizaj, T. F. ... Grgurevic, I. (2021). Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography. Digestive Diseases and Sciences, 67. (7), 3327-3332. doi: 10.1007/s10620-021-07277-8

Podrug, Kristian, et al. "Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography." Digestive Diseases and Sciences, vol. 67, br. 7, 2021, str. 3327-3332. https://doi.org/10.1007/s10620-021-07277-8

Podrug, Kristian, Vladimir Trkulja, Marko Zelenika, Tomislav Bokun, Anita Madir, Tajana Filipec Kanizaj, James O’Beirne i Ivica Grgurevic. "Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography." Digestive Diseases and Sciences 67, br. 7 (2021): 3327-3332. https://doi.org/10.1007/s10620-021-07277-8

Podrug, K., et al. (2021) 'Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography', Digestive Diseases and Sciences, 67(7), str. 3327-3332. doi: 10.1007/s10620-021-07277-8

Podrug K, Trkulja V, Zelenika M, Bokun T, Madir A, Kanizaj TF, i sur.. Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography. Digestive Diseases and Sciences [Internet]. 05.11.2021. [pristupljeno 14.12.2024.];67(7):3327-3332. doi: 10.1007/s10620-021-07277-8

K. Podrug, et al., "Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography", Digestive Diseases and Sciences, vol. 67, br. 7, str. 3327-3332, Studeni 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:264:591863. [Citirano: 14.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:264:591863
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography
AutorKristian Podrug
AutorVladimir Trkulja
AutorMarko Zelenika
AutorTomislav Bokun
AutorAnita Madir
AutorTajana Filipec Kanizaj
AutorJames O’Beirne
AutorIvica Grgurevic
Autorova ustanova(Klinička bolnica Merkur)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background and Aims We aimed to validate newly proposed noninvasive criteria for diagnosing clinically signifcant portal hypertension (CSPH) using liver stifness measurements (LSM) by transient elastography (TE) and platelet count. Methods Diagnostic performance of these new criteria for CSPH (LSM≥25 kPa to rule in and Plt≥150× 109 /L+LSM≤1 5 kPa to rule out CSPH) were retrospectively tested in an independent cohort of consecutive patients who underwent hepatic venous pressure gradient (HVPG) measurements and liver biopsy due to suspicion of compensated advanced chronic liver disease. Suspicion of cACLD was based on LSM≥10 kPa by TE or results of liver imaging, without overt signs of CSPH. Patients with conditions known to afect results of LSM (ALT>5×ULN, liver congestion, extrahepatic biliary obstruction, infltrative liver neoplasms) were excluded. Results Seventy six (76) patients were included: 78.9% males, mean age 62 years, 36.8% sufered from alcoholic, 30.3% nonalcoholic fatty liver disease, 14.5% chronic viral hepatitis, 30.3% were obese, 52.6% had HVPG≥10 mmHg, 56.6% had platelet count≥150× 109 /L. LSM≥25 kPa had 88.9% specifcity (95% CI 73.9– 96.9) to rule in, whereas Plt≥150+LSM≤15 kPa had 100% sensitivity (95% CI 91.1–100) to rule out CSPH. Conclusion By using these simple noninvasive criteria 49/76 (64.5%) patients could be classifed correctly for the presence/ absence of CSPH, thus obviating the need for HVPG measurements.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDigestive Diseases and Sciences
Brojčani podacivol. 67, br. 7, str. 3327-3332
p-ISSN0163-2116
DOIhttps://doi.org/10.1007/s10620-021-07277-8
URN:NBNurn:nbn:hr:264:591863
Datum objave publikacije2021-11-05
URL dokumentahttps://link.springer.com/article/10.1007/s10620-021-07277-8
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-12-20 10:03:40